- Home
- CERS vs OABI Comparison
CERS vs OABI Comparison
Compare CERS & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- OABI
- Stock Information
- Founded
- CERS 1991
- OABI 2012
- Country
- CERS United States
- OABI United States
- Employees
- CERS N/A
- OABI N/A
- Industry
- CERS EDP Services
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- CERS Technology
- OABI Health Care
- Exchange
- CERS Nasdaq
- OABI Nasdaq
- Market Cap
- CERS 255.0M
- OABI 228.9M
- IPO Year
- CERS 1997
- OABI N/A
- Fundamental
- Price
- CERS $1.23
- OABI $1.64
- Analyst Decision
- CERS Strong Buy
- OABI Strong Buy
- Analyst Count
- CERS 2
- OABI 3
- Target Price
- CERS $3.50
- OABI $6.67
- AVG Volume (30 Days)
- CERS 1.1M
- OABI 419.6K
- Earning Date
- CERS 10-29-2025
- OABI 11-11-2025
- Dividend Yield
- CERS N/A
- OABI N/A
- EPS Growth
- CERS N/A
- OABI N/A
- EPS
- CERS N/A
- OABI N/A
- Revenue
- CERS $192,510,000.00
- OABI $23,027,000.00
- Revenue This Year
- CERS $30.03
- OABI N/A
- Revenue Next Year
- CERS $9.37
- OABI $44.99
- P/E Ratio
- CERS N/A
- OABI N/A
- Revenue Growth
- CERS 13.25
- OABI 6.05
- 52 Week Low
- CERS $1.12
- OABI $1.22
- 52 Week High
- CERS $2.24
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- CERS 44.31
- OABI 43.98
- Support Level
- CERS $1.17
- OABI $1.55
- Resistance Level
- CERS $1.35
- OABI $1.73
- Average True Range (ATR)
- CERS 0.07
- OABI 0.10
- MACD
- CERS -0.00
- OABI 0.00
- Stochastic Oscillator
- CERS 22.22
- OABI 30.59
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.